Independent Health & Biomedical Research

Correction, 4 October 2026. This article was first published 4 June 2026 with errors, corrected here against the source papers. The Marks paper was dated 2025; it was published 29 April 2026. Its senior author was attributed to the Weissman lab; the work is from Brian Brown's group at Mount Sinai. "Mört" was a misspelling; the first author is Mörz. The frameshifting rate was given as 0.5 to 1 percent; the paper reports frameshifted product at about 8 percent of in-frame reporter protein. The two autopsy findings were labelled "confirmed autoimmune myocarditis" and "confirmed autoimmune hepatitis"; the paper reports borderline histio-lymphocytic myocarditis in one case and chronic hepatitis in the context of pre-existing primary biliary cirrhosis in the other. The miRT origin paper was cited to Nature Biotechnology; it is Nature Medicine 2006. Overstated framing throughout was rewritten to what the papers show. ...

Independent codon-usage analysis of the vaccine sequences, the Wuhan-Hu-1 reference, and a 21-genome sarbecovirus panel: the RSCU readings, the CGG codon counts across the panel, and where the held data answer the origin question and where they go quiet.

Correction, 4 October 2026. This article was first published 29 March 2026 claiming to validate Jean-Claude Perez's 2020 numerical observation. The following claims are withdrawn. The "82.6 percent validation" figure was a ratio of two percentage differences (26.1 divided by 31.6), which is not a validation metric. The Z-scores of 68 to 91 were artifacts of comparing viral genes against a housekeeping-gene baseline (22.1±3.4 ruptures/kb) that every viral sequence violates by two orders of magnitude; they are not quotable, and the article's own results table was irreconcilable with that baseline. "All natural viruses use -1 PRF" is false: programmed +1 frameshifting exists in nature, the bacterial release-factor-2 gene prfB being the standard textbook example. The "8-10 percent frameshifting efficiency" figure misstated Mulroney et al. (2024), which reports frameshifted product at about 8 percent of in-frame reporter protein in a reporter construct, not a translation rate; the same correction was applied to two other articles on this site the same day. The gain-of-function framing was wrong: the 2P substitutions are published, intentional prefusion-stabilisation design, and the product is a vaccine, not a virus. A melanoma tumour-growth claim attributed to Rubio-Casillas et al. was removed as unverified against the paper, which is a narrative review. A "Monroe et al. 2024" reference could not be traced and is removed. An "A-" self-grade and a "new scientific contribution" claim are removed. What survives is below, stated at the strength the evidence bears. ...

Manufacturing switch, DNA contamination, spike persistence, IgG4 immune tolerance, amyloid microclots, and regulatory failure converge on one conclusion: mRNA experiments must halt until safety is demonstrated.

The scientific case for pausing NIAID's intranasal whole-virus platforms: direct olfactory-nerve access to the brain, full structural proteins including spike, and the exact networks mapped in 2025 now running U.S. policy.

A write-up of Dr. Typhaine Pinsolle's integrated framework on the SARS-CoV-2 spike, the COVID mRNA injections, and the lab-origin question, with the strongest evidence stated plainly, the speculative labelled hypothesis, the counter-evidence engaged, and superseded statistics recorded.

What the post-COVID opportunistic-infection evidence shows: documented mechanisms (lymphopenia, interferon suppression, microbiome disruption), high-risk pathogens with incidence figures, and a supportive-care framework graded to its actual trial base.

Embalmer and mortuary reports of rubbery clots, a single investigator proteomic analysis, established PAD4 and NETosis cell biology, and the untested bridge between them. No peer-reviewed series; claims scoped by the 4 October 2026 correction.

Declaration of Purpose This analysis promotes scientific transparency and informed consent. All data are cited from primary or peer-reviewed sources where available; expert reports and preprints are flagged as such. No medical advice is given; evidence is shared for public understanding. Claims carry evidence tags under the system documented on the Methodology page. This content is for educational purposes only. Not medical advice; consult healthcare providers before therapeutic use. TL;DR# Core finding. Multiple SARS-CoV-2 proteins (ORF8, ORF7a, ORF3a, and the Omicron-era E mutation) suppress MHC-I, creating a functional analogy to HIV-1 Nef's immune-evasion outcome (not mechanistic identity). This is supported by peer-reviewed cell and structural studies. PP + MECHANISTIC · HIGH for the MHC-I downregulation claim itself. ...

Niclosamide graded claim by claim: established tapeworm use, one positive 2025 COVID RCT (CP-COV03 nanohybrid, n=300), cancer signals in phase I/II, everything else preclinical. The formulation lesson and what it does not license.

Evidence-graded review of black seed oil (Nigella sativa) benefits, incorporating recent meta-analyses and systematic reviews. Separates clinical proof from traditional use and emerging research.

The fundamental questions that remain unanswered about DNA contamination, SV40 promoters, and long-term safety; questions that should have been resolved before mass deployment.